Aisenberg AC. Problems in Hodgkin's disease management. Blood. 1999;93:761-779.
Bertelsen L, Mellemkjaer L, Christensen J, Rawal R, Olsen JH. Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives. Epidemiology. 2009;20:175-180.
Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781-785.
Bostrom PJ, Soloway MS. Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? Eur Urol. 2007;52:973-982.
Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat. 2007;106:439-451.
Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007;99:1634-1643.
Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma andadenocarcinoma of the cervix. J Clin Oncol. 2009 Feb 20;27(6):967-73.
Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. Accessed at www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf on 12/20/11.
Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol. 2008;26:1850-1857.
Karlsson CT, Malmer B, Wiklund F, Grönberg H. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer? J Urol. 2006;176:538-543.
Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:1195-1203.
Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107:991-998.
Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol. 2006;24:1568-1574.
Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J. 2008 Nov-Dec;14(6):429-34.
Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008;180:2005-2009; discussion 2009-10.
Richiardi L, Scélo G, Boffetta P, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer. 2007;120:623-631.
Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003;21:1195-1204.
Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev. 2006;15.
Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354-1365.
Travis LB, Hodgson D, Allan JM, Van Leeuwen FE. Second Cancers. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 8th edition. Philadelphia: Lippincott William & Wilkins: 2008:2718-2743.
Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108-115.
Last Medical Review: 01/30/2012
Last Revised: 01/30/2012